Genmab A/S
GMAB
$20.25
$0.050.25%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 30.38% | 19.69% | 21.14% | 22.04% | 17.77% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.38% | 19.69% | 21.14% | 22.04% | 17.77% |
| Cost of Revenue | 335.25% | 672.11% | 2,640.25% | -- | -- |
| Gross Profit | 26.14% | 15.72% | 17.60% | 19.23% | 16.16% |
| SG&A Expenses | 16.94% | 9.73% | 18.08% | 24.87% | 27.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.98% | 26.82% | 36.10% | 39.37% | 40.19% |
| Operating Income | 31.22% | 7.29% | -1.96% | -3.39% | -11.76% |
| Income Before Tax | 61.34% | 26.66% | 35.23% | 12.69% | -15.38% |
| Income Tax Expenses | 3.01% | 79.50% | 77.36% | 20.93% | -10.58% |
| Earnings from Continuing Operations | 78.55% | 13.42% | 24.66% | 10.46% | -16.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 78.55% | 13.42% | 24.66% | 10.46% | -16.70% |
| EBIT | 31.22% | 7.29% | -1.96% | -3.39% | -11.76% |
| EBITDA | 31.74% | 7.50% | -1.70% | -3.41% | -11.74% |
| EPS Basic | 82.23% | 14.72% | 25.03% | 10.59% | -16.59% |
| Normalized Basic EPS | 74.33% | 29.25% | 33.12% | 4.80% | -27.21% |
| EPS Diluted | 82.42% | 14.95% | 25.25% | 10.66% | -16.61% |
| Normalized Diluted EPS | 74.56% | 29.51% | 33.36% | 4.86% | -27.24% |
| Average Basic Shares Outstanding | -1.74% | -1.03% | -0.33% | -0.11% | -0.10% |
| Average Diluted Shares Outstanding | -1.89% | -1.17% | -0.44% | -0.14% | -0.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
